The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling
Open accessAbstract
Whether a gut-joint axis exists to regulate osteoarthritis is unknown. In two independent cohorts, we identified altered microbial bile acid metabolism with reduced glycoursodeoxycholic acid (GUDCA) in osteoarthritis. Suppressing farnesoid X receptor (FXR)—the receptor of GUDCA—alleviated osteoarthritis through intestine-secreted glucagon-like peptide 1 (GLP-1) in mice. GLP-1 receptor blockade attenuated these effects, whereas GLP-1 receptor activation mitigated osteoarthritis. Osteoarthritis patients exhibited a lower relative abundance of Clostridium bolteae , which promoted the formation of ursodeoxycholic acid (UDCA), a precursor of GUDCA. Treatment with C. bolteae and Food and Drug Administration–approved UDCA alleviated osteoarthritis through the gut FXR–joint GLP-1 axis in mice. UDCA use was associated with lower risk of osteoarthritis-related joint replacement in humans. These findings suggest that orchestrating the gut microbiota–GUDCA–intestinal FXR–GLP-1–joint pathway offers a potential strategy for osteoarthritis treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut dysbiosis has been implicated in RA-associated immune activation, whereas modulation of microbial BA metabolism and glucagon-like peptide-1 secretion has emerged as a potential therapeutic route in OA [130].”
From Interorgan Communications in Skeletal Pathophysiology: From Molecular Pathways to Multidisciplinary Therapies (2026) · cites this paper as [130]
Citations
Cites
Radiological Assessment of Osteo-Arthrosis
Kellgren, J., & Lawrence, J. S. (1957) · Annals of the Rheumatic Diseases · doi:10.1136/ard.16.4.494 · Cited by 12,472
Li, D., Liu, C.-M., Luo, R., Sadakane, K., & Lam, T. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv033 · Cited by 10,133
Hunter, D. J., & Bierma‐Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 5,127
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
SOAP2: an improved ultrafast tool for short read alignment
Li, R., Yu, C., Li, Y., Lam, T., Yiu, S., Kristiansen, K., & Wang, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp336 · Cited by 3,763
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlstrom, A. M., Sayin, S. I., Marschall, H., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,969
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Introduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
Multivariable association discovery in population-scale meta-omics studies
Mallick, H., Rahnavard, A., McIver, L. J., Ma, S., Zhang, Y., Nguyen, L. H., Tickle, T. L., Weingart, G., Ren, B., Schwager, E. H., et al. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009442 · Cited by 2,596
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- S. Hawley A. Delmestri A. Judge C. J. Edwards C. Cooper N. K. Arden D. Prieto-Alhambra “Total Hip and Knee Replacement Among Incident Osteoarthritis and Rheumatoid Arthritis Patients Within the UK Clinical Practice Research Datalink (CPRD) Compared to Hospital Episode Statistics (HES): A Validation Study ” paper presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management Dublin Ireland 25 to 28 August 2016.
Cited by
Sorted by citations
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
Osteoarthritis as a systemic disease
Collins, K. H., Haugen, I. K., Neogi, T., & Guilak, F. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01332-8 · Cited by 58
“Although initial studies aimed to understand the role of the gut microbiome as a link between diet and OA 135–138 , data now indicate that the gut microbiota–GLP1 axis could be a highly attractive drug target for OA 47 .”
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
“It demonstrated that GLP-1 RAs can modulate intestinal farnesoid X receptor (FXR) signaling to improve joint health [168].”
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 31
“People with OA have lower serum GLP-1 levels 63 , and intra-articular liraglutide injection alleviates pain 55 and attenuates cartilage degradation in OA mouse models 63 .”
Influential3D bioprinting bone/cartilage organoids: construction, applications, and challenges
Gao, D., Li, R., Pan, J., Li, C., Zhang, W., Qin, L., & Lai, Y. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.08.008 · Cited by 22
“Epidemiological data from the World Health Organization reveal that osteoarthritis alone affects over 500 million individuals globally, with prevalence rates surpassing 20 % in populations aged 65 years and older [4].”
Self-citation
Metadata
- Authors
- Yang, Y., Hao, C., Jiao, T., Yang, Z., Li, H., Zhang, Y., Zhang, W., Doherty, M., Sun, C., Yang, T., Li, J., Wu, J., Zhang, M., Wang, Y., Xie, D., Wang, T., Wang, N., Huang, X., Li, C., Gonzalez, F. J., Wei, J., Xie, C., Zeng, C., & Lei, G.
- Affiliations
- Central South University (CN)
- Chinese Academy of Sciences (CN)
- Harvard University (US)
- University of Nottingham (GB)
- Nanjing University of Chinese Medicine (CN)
- University of Toronto (CA)
- National Institutes of Health (US)
- Corresponding author
- Yang, Yuanheng
- Hao, Cong
- Jiao, Tingying
- Yang, Zidan
- Li, Hui
- Wei, Jie
- Xie, Cen
- Zeng, Chao
- Lei, Guanghua
- ORCID
- Venue
- Science
- Published
- 2025-04-04
- Volume
- 388
- Issue
- 6742
- Pages
- eadt0548-eadt0548
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4409176469
- Cited by
- 160
- References
- 91
- Citations by year
- 2026: 110 · 2025: 50
- FWCI
- 47.42
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (82 372 474, 2022YFC2505500, 81930071, 2022YFC3601900)
- Peking University
- Xiangya Hospital, Central South University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- osteoarthritis, gut-joint axis, glucagon-like peptide-1, farnesoid X receptor, glycoursodeoxycholic acid, bile acid metabolism, gut microbiota, Clostridium bolteae, ursodeoxycholic acid, GLP-1 receptor, joint replacement, microbiota-targeted therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Clostridium, Female, Humans, Male, Mice, Inbred C57BL, Osteoarthritis, Ursodeoxycholic Acid, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
